American HealthCare Capital is pleased to introduce a Pharmaceutical and Biotech Consulting firm for sale located in Pennsylvania and California. Founded in 1993, the business is a statistical consulting firm whose clients consist of pharmaceutical and biotech companies. The Company specializes in supporting statistical data analysis and reporting for clinical research, and they are a key player in assisting pharma companies to win new drug approvals from the FDA.

The business has increased the top and bottom line over the past several years. In the year ending 2019, total revenue was $5.258 million with an EBITDA of $873,000. In the pandemic year of 2020, the company accomplished a 15% growth rate to a total revenue of $6.045 million and an EBITDA of $826,000. The next two years, 2021 and 2022, the business had its best back-to-back years with 26% and 25% growth respectively. The company ended 2021 with $7.614 million in total sales with an EBITDA of $997,000. In the year ending 2022, total sales were $8.951 million with an EBITDA of $1.58 million. Based on results through the first half of 2023, the projected YE Revenue will be $10.5 million with an EBITDA of $1.8 million. The business is still growing, and the future looks very profitable as they continue to add valuable clients.

The current owner is pursuing the sale to semi-retire and concentrate on other businesses he has ownership in. To facilitate a successful and orderly transition, he is willing to remain with the Company during a transitional period. He will ensure that the new buyers have met all the key clients and understand the operations’ day-to-day function. The owner is also open to staying on as a consultant or part-time employee if needed after the transition.

The asking price for this opportunity is $14 million.

If you would like to learn more, please use the link on the right-hand side of the page to execute our NDA. You will need to copy the Listing Code (Example: TXMC1A) and Listing Title (Example: $1 Million Home Health Agency in Texas) from the summary above to complete the NDA.